Bli medlem
Bli medlem

Du är här


Biocartis Group NV: Biocartis receives EUR 2.5m strategic grant from Flemish government to support manufacturing capacity expansion

PRESS RELEASE:Tuesday, 18 October 2016, 07:00 CEST

Biocartis receives EUR 2.5m strategic grant from Flemish government to support
manufacturing capacity expansion

Minister Muyters, Flemish Minister of Work, Economy, Innovation and Sports
visits Biocartis on 18 October 2016 to announce the grant

Mechelen, Belgium
October 2016 -
Biocartis Group NV ('Biocartis'), an innovative molecular diagnostics company
(Euronext Brussels: BCART), today announces that it has received a EUR 2.5m
grant from the Flemish Agency for Innovation&Entrepreneurship under its
Strategic Transformation Support ('STS') program. Biocartis has received the
STS grant in order to support the manufacturing capacity expansion for its
Idylla(TM) diagnostics tests as well as to support the training and education
of existing and new personnel necessary to operate a new manufacturing line
that will be installed in Mechelen.

Ewoud Welten, CFO of Biocartis, commented:
"Biocartis is grateful for the financial support it has received from the
Flemish government. This is demonstrating the continued commitment of the
government to invest in innovation and growth in the Flemish region. The STS
grant that we received will further enable us in realising the required
expansion of our manufacturing capacity. However and equally important, it
will also support our ongoing investment in dedicated people, who in the end
are the ones that drive the availability of our high precision and cost
effective solutions to customers and patients."

Biocartis is honoured to announce that Minister Muyters will inform Biocartis
and its employees about the awarded STS grant during a visit to the company's
headquarters in Mechelen, Belgium on 18 October 2016.

Minister Muyters, the Flemish Minister of Work, Economy, Innovation and
Sports, commented:"

The STS program supports projects that make a significant contribution to the
strengthening of the economic development in Flanders. The manufacturing
expansion project that is ongoing at Biocartis is an excellent example of
this. We as government are pleased to be in the position to further stimulate
smart and disruptive innovation in Flanders, as showcased by Biocartis."

Minister Muyters will be accompanied by a delegation of the Flemish Investment
Company 'ParticipatieMaatschappij Vlaanderen' (PMV) consisting of Michel
Casselman (General Manager) and Roald Borré (Head of Equity Investments).

--- END ---

More information:

Renate Degrave
Manager Corporate Communications&Investor Relations

+32 15 631 729

About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has five oncology tests and two infectious disease tests. More information: Photo Library availablehere. Follow us onTwitter:

Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company or, as appropriate, the Company
directors' current expectations and projections concerning future events such
as the Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in which the
Company operates. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that could
cause actual results or events to differ materially from those expressed or
implied by the forward-looking statements. These risks, uncertainties,
assumptions and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition and technology,
can cause actual events, performance or results to differ significantly from
any anticipated development. Forward-looking statements contained in this
press release regarding past trends or activities are not guarantees of
future performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even if
actual results or developments are consistent with the forward-looking
statements contained in this press release, those results or developments may
not be indicative of results or developments in future periods. As a result,
the Company expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or representatives
nor any of its subsidiary undertakings or any such person's officers or
employees guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any responsibility for
the future accuracy of the forward-looking statements contained in this press
release or the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak only as
of the date of this press release.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.